A point-of-care diagnostic system that includes a cartridge and a reader. The cartridge can contain a patient sample, such as a blood sample. The cartridge is inserted into the reader and the patient sample is analyzed. The sample can be processed for data collection and analysis to provide interpretative results indicative of a disorder, condition, disease and/or infection of the patient. For example, the data collection and analysis can differentiate between two or more species capable of causing or actually causing a parasitic infection.

It was discovered that hydrogel scaffolds can be used to induce phase separation as aqueous two-phase systems (ATPSs) pass through and/or rehydrate the scaffolds, allowing for concentration of target analyte(s) (e.g., biomolecule(s)) into a particular phase of the ATPS or into a leading front. Accordingly, in various embodiments methods and devices are provided that utilize aqueous two-phase systems and hydrogel scaffolds to improve the sensitivity of assays (e.g., of point-of-care assays) without sacrificing cost or ease of use.

The present invention relates to a kiosk type urine analyzer and a health monitoring system using the same and relates to a kiosk type urine analyzer capable of analyzing urine of a user in an unmanned manner to provide an analysis result and monitoring health of the user through the analysis result, and a health monitoring system using the same.

Systems and methods for processing sensor data and end of life detection are provided. In some embodiments, a method for determining the end of life of a continuous analyte sensor includes evaluating a plurality of risk factors using an end of life function to determine an end of life status of the sensor and providing an output related to the end of life status of the sensor. The plurality of risk factors may be selected from the list including the number of days the sensor has been in use, whether there has been a decrease in signal sensitivity, whether there is a predetermined noise pattern, whether there is a predetermined oxygen concentration pattern, and error between reference BG values and EGV sensor values.

Systems and methods are provided for improving nutritional element content estimates from one or more individuals and/or determining a therapy or treatment based on a nutritional element content estimate and improving diabetes management. The systems and methods include a therapy or treatment display based on at least one nutritional element content estimate and at least one proficiency index respectively assigned to an individual to improve accuracy and reliability when estimating nutritional element content in foods and/or therapy or treatment based therefrom.

An apparatus and system diabetes management. The apparatus comprises a body which houses: (i) at least a first memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen and the patient's blood-glucose-level measurements determined at a plurality of times; (ii) a processor operatively connected to the at least first memory, the processor programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components of the patient's present insulin dosage regimen; (iii) a display screen operatively connected to the processor; (iv) a quantity of insulin; (v) a needle communicating with the quantity of insulin for delivering insulin to the patient; (vi) means for effecting delivery of a portion of the quantity of insulin to the patient via the needle; and (vii) metering means for controlling the portion of the quantity of insulin delivered to the patient via the needle.

According to some embodiments of the present disclosure, a device and method for determining an allowable amount of blood glucose (bG) of a patient is disclosed. The method further includes receiving a current bG measurement, determining a target bG value, and determining a correction delta bG value based on one or more advice history records. The method includes determining a correction meal rise value and determining a maximum allowed bG value based on the target bG value, the correction delta bG value, and the correction meal rise value. The method includes setting the allowable amount of bG value equal to the maximum allowed bG value when the current bG measurement is greater than the target bG value and determining the allowable amount of bG value using the target bG value and the correction delta bG value when the current bG measurement is less than the target bG value.

Disclosed are methods and systems for high-throughput testing of pathogens, and in some instances, testing for SARS-CoV-2. For example, disclosed is a method for intelligently selecting samples to perform a pooled testing for a pathogen including the steps of obtaining samples from multiple regions/populations, determining a prevalence of the pathogen in the samples from each region/population, determining an optimal selection plan to perform the pooled testing, selecting and combining samples based on the optimal selection plan, aliquoting the samples in the combined sample set based on the optimal selection plan, pooling and testing the samples in the combined sample set based on the optimal pooling design to determine a presence or absence of a detectable amount of the pathogen in each of the pooled samples, and determining whether at least one individual sample comprises the detectable amount of the pathogen.

The embodiments disclose a method including functionalizing a biosensor with a biologic analytical target prior to installation into a detection cartridge, depositing a test subject bodily fluid test sample onto the biosensor surface, inserting the detection cartridge into a portable detection cartridge reader, measuring the electrical impedance of the bodily fluid test sample across biosensor energized electrodes, providing algorithms for analyzing measured electrical impedance data of the bodily fluid test sample obtained in the detection cartridge, identifying and determining the presence of biologic analytical target molecules in the bodily fluid test sample, and transmitting results of the test results to the test subject.

A method for the analysis, in particular for analysis by dynamic difference calorimetry (DSC), of biological material, in particular blood, urine, sweat or skin tissue, with the steps of: introduction of a sample with a patient's biological material onto a sensor of a measuring device; acquisition of measured values by means of the measuring device; sending the measured values to an evaluation device, which communicates with the measuring device; assessment of the patient's state of health with the aid of data structures characterizing the state of health on the basis of the measured values by means of the evaluation device, on which a first application software instance is performed; and visualization or audio-visualization of the state of health on a display. The present invention further creates a system for the analysis of biological material and a use of such a system.